在线PSMA PET引导放疗用于寡转移性前列腺癌的可行性研究
本研究基于15例激素敏感性寡转移性前列腺癌患者的PSMA靶向18F-DCFPyL PET/CT影像,利用研究型治疗计划系统模拟生物学引导放疗(BgRT),并与临床SABR及研究型SABR比较剂量分布。结果显示BgRT在维持相似PTV覆盖和适形度的同时,Dmax平均增加18%,危及器官平均剂量降低10%,且剂量与PET摄取相关性更高。
要点
- BgRT计划相比临床SABR,PTV Dmax平均增加18%,危及器官平均剂量降低10%。
- BgRT与临床SABR的PTV覆盖和适形度相似,适形指数分别为0.72和0.74。
- 剂量与log(SV)的Pearson相关系数在BgRT中为0.31,高于临床SABR的0.10。
核心结论
- BgRT计划在纳入PET活性的同时,提供了与临床SABR相似的PTV覆盖和适形度,证明在线PSMA靶向、基于PET追踪的剂量递送对寡转移性前列腺癌可行。
研究设计与样本
- 研究使用研究型治疗计划系统对15例既往接受临床SABR的激素敏感性寡转移性前列腺癌患者进行重计划,患者均有PSMA靶向18F-DCFPyL PET/CT影像。
- 研究型治疗计划系统模拟了一种集成PET和千伏级CT成像子系统的环形安装原型直线加速器,可优化BgRT计划和不使用放射性示踪剂引导的研究型SABR计划。
主要发现
- 剂量与log(特异性摄取值的) Pearson相关系数分别为0.10(临床SABR)、0.16(研究型SABR)和0.31(BgRT)。
临床怎么用
- 对于寡转移性前列腺癌,基于PSMA PET的BgRT可在维持靶区覆盖和适形度的同时提高靶区最大剂量并降低危及器官剂量,但尚处研究阶段。
局限性
- 本研究为基于15例患者影像的治疗计划模拟研究,非实际治疗实施,结果需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic ablative radiation therapy (SABR) for oligometastatic prostate cancer (OMPC) may improve clinical outcomes, but current challenges in intrafraction tracking of multiple small targets limits treatment accuracy. A biology-guided radiation therapy (BgRT) delivery system incorporating positron emission tomography (PET) detectors is being developed to use radiotracer uptake as a biologic fiducial for intrafraction tumor tracking to improve geometric accuracy. This study simulates prostate-specific membrane antigen (PSMA)-directed BgRT using a cohort from our phase II randomized trial of SABR in men with recurrent hormone sensitive OMPC and compares dose distributions to clinical SABR (CSABR). METHODS AND MATERIALS: A research treatment planning system (RTPS) was used to replan 15 patients imaged with PSMA-targeted 18F-DCFPyL PET/computed tomography and previously treated with CSABR using conventional linear accelerators (linacs). The RTPS models a prototype ring-mounted linac incorporating PET and kilo-voltage computed tomography imaging subsystems and can be used to optimize BgRT plans, as well as research SABR (RSABR) plans, which use the prototype linac without radiotracer guidance. CSABR, RSABR, and BgRT plans were compared in terms of maximum planning target volume (PTV) dose (Dmax), mean dose to proximal organs at risk (DOAR), conformity index, as well as voxel-wise correlation of dose with PET specific uptake values to investigate possible dose-painting effects. RESULTS: RSABR and BgRT plans resulted in mean ± standard deviation increases in Dmax of 4 ± 11% (P = .21) and 18 ± 15% (P < .001) and reductions in DOAR of -20 ± 19% (P <.001) and -10 ± 19% (P = .02) compared with CSABR. Similar target coverage was maintained with conformity indices of 0.81 ± 0.04 (P < .001) and 0.72 ± 0.08 (P = .44) for RSABR and BgRT compared with 0.74 ± 0.08 for CSABR. Dose and log (specific uptake values) had Pearson correlation coefficients of 0.10 (CSABR), 0.16 (RSABR), and 0.31 (BgRT). CONCLUSIONS: BgRT plans provided similar PTV coverage and conformity compared with CSABR while incorporating underlying PET activity. These results demonstrate feasibility of BgRT optimization enabling online PSMA-targeted, PET-based tracked dose delivery for OMPC.
引用
- Hrinivich WT, Phillips R, Da Silva AJ, et al. Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer. Adv Radiat Oncol. 2019. PMID: 32280826. doi:10.1016/j.adro.2019.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。